Remaxol
Phase 3Small molecule
Remaxol is one of 17 small molecule programs targeting Jaundice. It is currently in Phase 3.
3
Indications
5
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Jaundice
#DrugCompanyPhaseTrials
1Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Decadron
AAspen Global Incorporated
Phase 3
Cysteine Hydrochloride
NovartisPhase 2
Remaxol
PPOLYSAN Scientific & Technological Pharmaceutical Company
Phase 3
Stannsoporfin
IInfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Phase 2
Rocephin
CConrado Roberto Hoffmann Filho
Preclinical
Verazinc
FFakultas Kedokteran Universitas Indonesia
Preclinical
Glycerin
CCalm Water Therapeutics LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Jaundice2 trials
Remaxol® in Mechanical Jaundice of Non-malignant Origin
Completed·PPOLYSAN Scientific & Technological Pharmaceutical Company·Phase 3·NCT03418935·342 enrolled
Remaxol® in Malignant Mechanical Jaundice
Completed·PPOLYSAN Scientific & Technological Pharmaceutical Company·Phase 3·NCT03416062·240 enrolled
Intrahepatic Cholestasis1 trial
Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis
Completed·PPOLYSAN Scientific & Technological Pharmaceutical Company·Phase 2/3·NCT06183242·328 enrolled
Obstructive Jaundice1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Remaxol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details